Search jobs 03-Feb-2021 Global Addison’s Disease Drugs Market 2020:Size, Opportunities, Analysis And Forecast To 2027||Novartis AG, Pfizer Inc, Takeda Pharmaceutical Company Limited
Addison’s disease drugs market report carries out research and analysis of the market for a certain product/service which includes the investigation into customer inclinations. It performs the study of various customer capabilities such as investment attributes and buying potential. This market report involves feedback from the target audience to understand their characteristics, expectations, and requirements. The report provides new and exciting strategies for upcoming products by determining the category and features of products that the target audiences will readily accept. The global Addison’s disease drugs market research report collects data about the target market such as pricing trends, customer requirements, competitor analysis, and other s
Press release content from Business Wire. The AP news staff was not involved in its creation.
Takeda Completes Sale of TachoSil® to Corza Health
February 1, 2021 GMT
OSAKA, Japan (BUSINESS WIRE) Feb 1, 2021
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil ® Fibrin Sealant Patch (“TachoSil ® ”) to Corza Health, Inc. (“Corza”) for €350 million.
ADVERTISEMENT
TachoSil ® is a surgical patch trusted by medical professionals globally to deliver safe, fast and reliable bleeding control. Under the terms of the transaction, Corza has acquired the assets and licenses that support the development and commercialization of TachoSil®, while Takeda maintains ownership of the manufacturing facility in Linz, Austria. Takeda has entered into a long-term manufacturing & supply agreement, under which it will continue to exclusively manufacture TachoSil
Press release content from Business Wire. The AP news staff was not involved in its creation.
Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy
January 28, 2021 GMT
CAMBRIDGE, Mass. & OSAKA, Japan (BUSINESS WIRE) Jan 28, 2021
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced new data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in previously treated patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC) will be presented as a late-breaking oral session at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer (WCLC) on Friday, January 29 SGT.
Press release content from Newswire. The AP news staff was not involved in its creation.
PatientsLikeMe Partners With Takeda to Empower Patients and Elevate Patient Voice to the Level of Evidence
January 26, 2021 GMT
CAMBRIDGE, Mass. - January 26, 2021 - ( Newswire.com )
The world’s largest integrated community, health management, and real-world data platform PatientsLikeMe announced today it is partnering with Takeda Pharmaceutical Company Limited (“Takeda”). PatientsLikeMe announces a strategic partnership to optimize technology to enhance understanding of the patient experience and improve patients’ ability to partner effectively with their healthcare teams. PatientsLikeMe and Takeda will enhance the digital platform and gather insights on the patient experience and unmet needs, with an initial focus on Rare Diseases, Immunology, Neuroscience/Mental Health and Gastroenterology.